Immunity after HPV Vaccination in Patients after Sexual Initiation

Pruski, Dominik; Łagiedo‐Żelazowska, Małgorzata; Przybylski, Marcin; Sikora, Jan; Jach, Robert

doi:10.3390/vaccines10050728

Cited by 5 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same study also highlights that the duration of innate immunity is still unknown. On the contrary, HPV vaccination generates 10-to 100-fold higher titres of anti-HPV L1 neutralizing antibodies than natural infection (23) and significantly reduces the risk of invasive cervical cancer, which is the ultimate intent of HPV vaccination programmes (24). Our results suggest the high susceptibility of the young population in our province to HPV infection.…”

Section: Variablesmentioning

confidence: 64%

Human papillomavirus-specific antibody status among unvaccinated subjects in the region of Vojvodina, Serbia

Kovačević¹,

Nedeljković²,

Patić³

et al. 2023

Cent Eur J Public Health

View full text Add to dashboard Cite

Objectives:The aim of the study was to evaluate the immune status of young people from the Vojvodina province, Serbia, through the detection of IgG antibodies specific for the L1 protein of HPV types 6, 11, 16, and 18 contained in quadrivalent vaccine.Methods: The study enrolled 514 healthy persons of both genders, aged between 18 and 30 years. All potential participants were informed about the project's aims by trained interviewers before venous blood collection. Also, participants completed a specially designed anonymous questionnaire to identify socio-demographic characteristics and individual behaviours associated with HPV seroprevalence. VPL HPV L1-specific IgG antibodies were measured using a semi-quantitative HPV IgG ELISA kit (Dia.Pro, Italy).Results: A total of 472 (91.8%) young subjects had no detectable antibodies against high-and low-risk HPV types covered by the quadrivalent vaccine. A slightly higher number of seropositive individuals were detected in the age group of 26-30 years compared to younger than 25. Multivariate analysis showed that the number of lifetime sexual partners was the most powerful predictor of HPV seropositivity (OR = 3.483, 95% CI: 1.294-9.379).Conclusions: Obtained data point out low levels of naturally induced HPV-specific serum antibodies among the target population in the Vojvodina province. The present work highlights the significance and potential benefits of HPV vaccination. Routine HPV vaccination should be the public health priority in our country and should be included in the national immunization programme as soon as possible.

show abstract

Section: Variablesmentioning

confidence: 64%

Human papillomavirus-specific antibody status among unvaccinated subjects in the region of Vojvodina, Serbia

Kovačević¹,

Nedeljković²,

Patić³

et al. 2023

Cent Eur J Public Health

View full text Add to dashboard Cite

show abstract

“…Indeed, as reported by the VIANE trial, the immune response showed a low decrease between four and seven years after administration, indicating that the vaccine is capable of conferring an immune cover and promoting HPV clearance and lesion regression. This viewpoint is supported by experimental research that shows a higher level of IgG antibodies in women who received an anti-HPV nonavalent vaccine compared to unvaccinated subjects, demonstrating the vaccine’s efficacy also in women with a history of previous sexual intercourse, HPV infection, or LSIL diagnosis [ 45 ]. Some other studies, too, reported an increase in HPV antibody levels after vaccination that was three times higher than after HPV infection.…”

Section: Discussionmentioning

confidence: 89%

Low-Grade Cervical Intraepithelial Neoplasia (CIN1) Evolution: Analysis of Opportunistic Preventive Vaccination Role

et al. 2023

View full text Add to dashboard Cite

Background: Low-grade cervical lesions have a high percentage of clearance in young women, even if 71–82% of low-grade intraepithelial lesion/atypical squamous cells of undetermined significance (LSIL/ASCUS) reported a High-Risk Human Papillomavirus (HR-HPV) infection, which correlates with an increased risk of Cervical Intraepithelial Neoplasia (CIN)2+. The immunogenic effect of the anti-HPV vaccine appears to be significant. The aim of the study is to evaluate the effect, two years after the diagnosis, of the anti-HPV preventive vaccination on patients with low-grade cervical lesions. Methods: We collected clinical, colposcopic, histological, and virological data from patients aged 21–45 years who attended the colposcopy service of the department of Obsetrics and Gynecology of IRCCS Foundation Policlinico San Matteo, Pavia, Italy. In the 2005–2019 period and had a low-grade pap-smear. Results: We enrolled 422 women consecutively, divided into two groups (vaccinated and not vaccinated) for the retrospective analysis. The rate of persistence and progression of CIN were higher in the not-vaccinated group (p = 0.019). The relative risk (RR) to develop CIN2+ during follow-up vs. the the CIN1 persistence was 1.005 (95% Confidence Interval—CI 0.961–1.051) vs. 0.994 (95% CI 0.994–1.018) for age, 3.472 (95% CI 1.066–11.320) vs. 1.266 (95% CI 0.774–2.068) for non-vaccinated, 0.299 (95% CI 0.088–1.018) vs. 0.518 (95% CI 0.242–1.109) for HIV status negative, respectively. Analyzing the time to negativity, the odds ratio (OR) was 1.012 (95% CI 1–1.024) for age and 1.591 (95% CI 1.223–2.069) for vaccination; on the other hand, considering the relationship between the time to negative and the HPV genotypes contained in the 9-valent HPV vaccines, the OR was 1.299 (95% CI 1.026–1.646) for at least one of these at recruitment and 0.631 (95% CI 0.471–0.846) at follow-up. Furthermore, the presence of at least one of the HPV genotypes targeted by the HPV nonavalent vaccine is a key indicator of the risk of progression to CIN2+: OR was 3.443 (95% CI 1.065–11.189) for the presence of at least one HPV genotype at enrollment and 5.011 (95% CI 1.899–13.224) for the presence of at least one HPV genotype at follow-up, respectively. Conclusions: We reported in a retrospective study the benefit of anti-HPV vaccination in promoting negativity and increasing low-grade cervical lesions regression.

show abstract

“…Furthermore, mainly for the mean age of the patients, none of the patient was vaccinated against HPV, which could have affected HPV prevalence distribution. 24,25 Among potential limitations, the cross-sectional retrospective nature of the study and unavailability of some clinical information, which limited further analysis of potentially relevant factors such as smoking, immunodepression, or location of lesions.…”

Section: Resultsmentioning

confidence: 99%

Human papillomavirus genotyping in high‐grade vaginal intraepithelial neoplasia: A multicentric Italian study

Preti,

Boldorini,

Gallio

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

This study aimed to analyze the human papillomavirus (HPV) genotype distribution in a large cohort of high‐grade vaginal intraepithelial neoplasia (VaIN) (vaginal HSIL, VaIN2/3) patients from two Italian referral centers. We included all patients with histologically confirmed VaIN2/3 from the Department of Surgical Sciences, Sant'Anna Hospital, University of Torino, Torino, Italy, and Ospedale Maggiore della Carità, Novara, Italy, between 2003 and 2022. After the histological evaluation of formalin‐fixed paraffin‐embedded samples, we performed HPV genotyping with VisionArray HPV Chip 1.0. We detected HPV DNA in 94.4% of VaIN2/3 (168/178), with HPV 16 as the most prevalent genotype, accounting for 51.8% of all infections, 41.2% of VaIN2 and 77.6% of VaIN3 cases. Other frequent genotypes were HPV 58 (8.3%, 10.9% of VaIN2 and 2.0% of VaIN3), HPV 73 (5.4%, 5.0% of VaIN2 and 6.1% of VaIN3), and HPV 31 (5.4%, 6.7% of VaIN2 and 2.0% of VaIN3). 73.2% of VaIN2/3 had a single HPV genotype infection and 26.8% a multiple infection (20.8% a double infection, 4.8% a triple infection, and 1.2% a quadruple infection). Single infection was more frequently present in VaIN3 than VaIN2 (81.6% vs. 69.8%). 69.1% of single infections and 73.3% of multiple infections had one or more genotypes covered by nine‐valent HPV vaccine. HPV vaccination is expected to have a large impact on reducing the incidence of vaginal intraepithelial neoplasia.

show abstract

Immunity after HPV Vaccination in Patients after Sexual Initiation

Cited by 5 publications

References 29 publications

Human papillomavirus-specific antibody status among unvaccinated subjects in the region of Vojvodina, Serbia

Human papillomavirus-specific antibody status among unvaccinated subjects in the region of Vojvodina, Serbia

Low-Grade Cervical Intraepithelial Neoplasia (CIN1) Evolution: Analysis of Opportunistic Preventive Vaccination Role

Human papillomavirus genotyping in high‐grade vaginal intraepithelial neoplasia: A multicentric Italian study

Contact Info

Product

Resources

About